Detailed Report on Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Complete report available @ Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus Infections (AIDS) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 17, 43, 45, 2, 108, 75 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 15, 15, 51 and 67 molecules, respectively.

Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Abivax SA AdAlta Ltd Advanced Genetic Systems Inc Akshaya Bio Inc AlbaJuna Therapeutics Allergan Plc Altor BioScience Corp Altravax Inc Amarna Therapeutics BV American Gene Technologies International Inc Amunix Operating Inc Antigen Express Inc Aphios Corp Apotex Inc Argos Therapeutics Inc Arno Therapeutics Inc Atreca Inc B Cell Design SAS BioClonetics Immunotherapeutics Inc Biological Mimetics Inc Biosantech SA Biotron Ltd Boehringer Ingelheim GmbH Bolder Biotechnology Inc Bristol-Myers Squibb Company C4X Discovery Holdings PLC Calimmune Inc CEL-SCI Corp Celgene Corp Celldex Therapeutics Inc Chipscreen Biosciences Ltd CompleGen Inc ConjuChem LLC ContraVir Pharmaceuticals Inc Critical Outcome Technologies Inc Curevac AG Cytodyn Inc Dong-A Socio Holdings Co Ltd Enzo Biochem Inc EpiVax Inc eTheRNA Immunotherapies NV Etubics Corp Evofem Inc FIT Biotech Oy Formune SL Fountain Biopharma Inc Frontier Biotechnologies Co Ltd Galmed Pharmaceuticals Ltd GeneCure LLC GeoVax Labs Inc Gilead Sciences Inc GlaxoSmithKline Plc Globeimmune Inc GW Pharmaceuticals Plc H-Phar SA Hadasit Medical Research Services & Development Ltd Hanmi Pharmaceuticals Co Ltd Heat Biologics Inc ID Pharma Co Ltd IGXBio Inc Immune Response BioPharma Inc Immune Therapeutics Inc ImmunoClin Corp Immunocore Ltd Immunotope Inc ImQuest Life Sciences Inc InnaVirVax SA Innovative Targeting Solutions Inc Inovio Pharmaceuticals Inc Japan Tobacco Inc Johnson & Johnson Karyopharm Therapeutics Inc KPI Therapeutics Inc Kymab Ltd Longevity Biotech Inc MacroGenics Inc Medestea Research & Production SpA Medivir AB Merck & Co Inc Mologen AG Mymetics Corp Myrexis Inc NanoViricides Inc Navigen Pharmaceuticals Inc NeED Pharma srl New World Laboratories Inc Novartis AG Omeros Corp Oncolys BioPharma Inc OncoNOx ApS Oncovir Inc Orbis Biosciences Inc Osel Inc OyaGen Inc PaxVax Inc Peregrine Pharmaceuticals Inc Pfizer Inc Pharis Biotec GmbH PharmatrophiX Inc Phoenix Biotechnology Inc PlantForm Corp Profectus BioSciences Inc RAPID Pharmaceuticals AG ReceptoPharm Inc Recombio SL Relmada Therapeutics Inc Rodos BioTarget GmbH Samjin Pharmaceutical Co Ltd Sangamo BioSciences Inc Sanofi Sanofi Pasteur SA Savoy Pharmaceuticals Inc Serometrix LLC Sigma-Tau SpA Sirenas Marine Discovery LLC Solon Eiendom ASA Spider Biotech Spring Bank Pharmaceuticals Inc Staidson (Beijing) Biopharmaceuticals Co Ltd Starpharma Holdings Ltd Sumagen Co Ltd Susavion Biosciences Inc Taiga Biotechnologies Inc TaiMed Biologics Inc Takara Bio Inc Takeda Pharmaceutical Company Ltd TechnoVax Inc TeneoBio Inc TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Ltd TGV-Laboratories Theratechnologies Inc Theravectys SA Tomegavax Inc Transgene Biotek Ltd TVAX Biomedical Inc United Biomedical Inc Vaccibody AS Vault Pharma Inc VDA Pharma Inc VG Life Sciences Inc Vichem Chemie Research Ltd ViiV Healthcare Ltd Viriom Ltd ViroStatics srl XL-protein GmbH Zydus Cadila Healthcare Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###